Key facts
- It has raised $454.3M across 1 recorded rounds; the latest was Later Stage VC (Series B2) ($158.3M) in Apr 2024.
- Notable investors include RA Capital Management, Alexandria Venture Investments, Goldman Sachs Asset Management, Blue Owl Capital, Moore Strategic Ventures — 19 tracked in total.
- TORL BioTherapeutics has filed 1 Form D with the SEC, most recently Apr 2024 ($158.3M sold to 52 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for TORL BioTherapeutics
Funding rounds
1 roundsAbout TORL BioTherapeutics
Developer of a drug development company designed to focus on antibody-drug conjugates (ADCs) and other biologics. The company leverages target identification and early discovery work before electing to pull a drug program into the company under a novel license agreement, enabling researchers to develop proprietary drugs with unique and optimized profiles.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Culver City, CA, United States
- Founded
- 2018
- Employees
- 57
- Website
- torlbio.com/
- Ownership
- Privately Held (backing)
TORL BioTherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TORL BioTherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TORL BioTherapeutics in its N-PORT filings yet. We sweep new filings monthly.